Newly recognized side-effects of proton pump inhibitors: Arguments in favour of fundoplication for GERD?;Neu erkannte Nebenwirkungen von Protonenpumpeninhibitoren: Argumente Pro Fundoplicatio bei GERD?

Chirurg

Volumn 83, Issue 1, 2012, Pages 38-44

  von Rahden, B H A ^a   Scheurlen, M ^a   Filser, J ^a   Stein, H J ^b   Germer, C T ^a  

^a UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

^b KLINIKUM NÜRNBERG   (Germany)

Author keywords

Fundoplication; Gastroenterology; Gastroesophageal reflux disease; Proton pump inhibitors; Side effects

Indexed keywords

PROTON PUMP INHIBITOR;

COMPARATIVE STUDY; GASTROESOPHAGEAL REFLUX; HUMAN; LONG TERM CARE; REVIEW; STOMACH FUNDOPLICATION; TREATMENT OUTCOME;

FUNDOPLICATION; GASTROESOPHAGEAL REFLUX; HUMANS; LONG-TERM CARE; PROTON PUMP INHIBITORS; TREATMENT OUTCOME;

EID: 84855947432     PISSN: 00094722     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00104-011-2173-x     Document Type: Review

References (55)

1. Andrès E, Noel E, Abdelghani MB (2003) Vitamin B(12) deficiency associated with chronic acid suppression therapy. Ann Pharmacother 37: 1730.
2. Aseeri M, Schroeder T, Kramer J, Zackula R (2008) Gastric acid suppression by proton pump inhibitors as a risk factor for clostridium difficile-associated diarrhea in hospitalized patients. Am J Gastroenterol 103: 2308-2313.
3. Bhatt DL, Cryer BL, Contant CF et al (2010) Clopidogrel with or without omeprazole in coronary artery disease. N Engl J Med 363: 1909-1917.
4. Broeren MA, Geerdink EA, Vader HL, Wall Bake AW van den (2009) Hypomagnesium induced by several proton-pump inhibitors. Ann Intern Med 151: 755-756.
5. Charlot M, Ahlehoff O, Norgaard ML et al (2010) Proton-pump inhibitors are associated with increased cardiovascular risk independent of clopidogrel use: a nationwide cohort study. Ann Intern Med 153: 378-386.
6. Charlot M, Grove EL, Hansen PR et al (2011) Proton pump inhibitor use and risk of adverse cardiovascular events in aspirin treated patients with first time myocardial infarction: nationwide propensity score matched study. BMJ 342: d2690. DOI 10. 1136/bmj. d2690.
7. Collet JP, Hulot JS, Pena A et al (2009) Cytochrome P450 2C19 polymorphism in young patients treated with Clopidogrel after myocardial infarction: a cohort study. Lancet 373: 309-317.
8. Das D, Chilton AP, Jankowski JA (2009) Chemoprevention of oesophageal cancer and the AspECT trial. Recent Results Cancer Res 181: 161-169.
9. Dial S, Alrasadi K, Manoukian C et al (2004) Risk of Clostridium difficile diarrhea among hospital inpatients prescribed proton pump inhibitors: cohort and case-control studies. CMAJ 171: 33-38.
10. Dial S, Delaney JA, Barkun AN, Suissa S (2005) Use of gastric acid-suppressive agents and the risk of community-acquired Clostridium difficile-associated disease. JAMA 294: 2989-2995.
11. Epstein M, McGrath S, Law F (2006) Proton-pump inhibitors and hypomagnesemic hypoparathyroidism. N Engl J Med 17: 1834-1836.
12. European Medicines Agency (2009) Public statement on possible interaction between clopidogrel and proton pump inhibitors. www. ema. europa. eu/docs/en_GB/document_library/Public_statement/2009/11/WC500014409. pdf.
13. FDA Drug Safety Communication. Early communication about an ongoing safety review of clopidogrel bisulfate (marketed as Plavix). www. fda. gov/Drugs/DrugSafety/ucm079520. htm.
14. FDA Drug Safety Communication. Low magnesium levels can be associated with long-term use of proton pump inhibitor drugs (PPIs). www. fda. gov/Drugs/DrugSafety/ucm245011. htm.
15. FDA Drug Safety Communication (2009) Plavix (clopidogrel bisulfate) 75& mg tablets. Detailed view: safety labeling changes approved by FDA Center for Drug Evaluation and Research (CDER). www. fda. gov/Safety/MedWatch/SafetyInformation/ucm165166. htm.
16. Fiocca R, Mastracci L, Engström C et al (2010) Long-term outcome of microscopic esophagitis in chronic GERD patients treated with esomeprazole or laparoscopic antireflux surgery in the LOTUS trial. Am J Gastroenterol 105: 1015-1023.
17. Fossmark R, Johnsen G, Johanessen E, Waldum HL (2005) Rebound acid hypersecretion after long-term inhibition of gastric acid secretion. Aliment Pharmacol Ther 21: 149-154.
18. Galmiche JP, Hatlebakk J, Attwood S et al (2011) Laparoscopic antireflux surgery vs esomeprazole treatment for chronic GERD: The LOTUS randomized clinical trial. JAMA 305: 1969-1677.
19. Georgopoulos SD, Polymeros D, Triantafyllou K et al (2006) Hypergastrinemia is associated with increased risk of distal colon adenomas. Digestion 74: 42-46.
20. Gillen D, Wirz AA, Ardill JE, McColl KE (1999) Rebound hypersecretion after omeprazole and its relation to on-treatment acid suppression and Helicobacter pylori status. Gastroenterology 116: 239-247.
21. Gray SL, LaCroix AZ, Larson J et al (2010) Proton pump inhibitor use, hip fracture, and change in bone mineral density in postmenopausal women: results from the Women's Health Initiative. Arch Intern Med 170: 765-771.
22. Härmark L, Wiel HE van der, Groot MC de, Grootheest AC van (2007) Proton pump inhibitor-induced acute interstitial nephritis. Br J Clin Pharmacol 64: 819-823.
23. Herzig SJ, Howell MD, Ngo LH, Marcantonio ER (2009) Acid-suppressive medication use and the risk for hospital-acquired pneumonia. JAMA 301: 2120-2128.
24. Ho PM, Maddox TM, Wang L et al (2009) Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome. JAMA 301: 937-944.
25. Howell MD, Novack V, Grgurich P et al (2010) Iatrogenic gastric acid suppression and the risk of nosocomial Clostridium difficile infection. Arch Intern Med 170: 784-790.
26. Islami F, Kamangar F, Boffetta P (2009) Use of proton pump inhibitors and risk of progression of Barrett's esophagus to neoplastic lesions. Am J Gastroenterol 104: 2646-2648.
27. Katz MH (2010) Failing the acid test: Benefits of proton pump inhibitors may not justify the risks for many users. Arch Intern Med 170: 747-748.
28. Klinkenberg-Knol EC, Nelis F, Dent J et al (2000) Long-term omeprazole treatment in resistant gastroesophageal reflux disease: efficacy, safety, and influence on gastric mucosa. Gastroenterology 118: 661-669.
29. Koop H, Schepp W, Müller-Lissner S et al (2005) Gastroösophageale Refluxkrankheit - Ergebnisse einer evidenzbasierten Konsensuskonferenz der Deutschen Gesellschaft für Verdauungs- und Stoffwechselkrankheiten. Z Gastroenterol 43: 163-164.
30. Kwok CS, Yeong JK, Loke YK (2011) Meta-analysis: risk of fractures with acid-suppressing medication. Bone 48: 768-776.
31. Laheij RJ, Sturkenboom MC, Hassing RJ et al (2004) Risk of community-acquired pneumonia and use of gastric acid-suppressive drugs. JAMA 292: 1955-1960.
32. Laine L, Hennekens C (2010) Proton pump inhibitor and clopidogrel interaction: Fact or fiction? Am J Gastroenterol 105: 34-41.
33. McColl KE, Gillen D (2009) Evidence that proton-pump inhibitor therapy induces the symptoms it is used to treat. Gastroenterology 137: 20-22.
34. Mega JL, Close SL, Wiviott SD et al (2009) Cytochrome p-450 polymorphisms and response to clopidogrel. N Engl J Med 360: 354-362.
35. Miano TA, Reichert MG, Houle TT et al (2009) Nosocomial pneumonia risk and stress ulcer prophylaxis: a comparison of pantoprazole vs ranitidine in cardiothoracic surgery patients. Chest 136: 440-447.
36. Ngamruengphong S, Leontiadis GI, Radhi S et al (2011) Proton pump inhibitors and risk of fracture: a systematic review and meta-analysis of observational studies. Am J Gastroenterol [Epub ahead of print].
37. Nguyen DM, El-Serag HB, Henderson L et al (2009) Medication usage and the risk of neoplasia in patients with Barrett's esophagus. Clin Gastroenterol Hepatol 7: 1299-1304.
38. Ray S, Delaney M, Muller AF (2010) Proton pump inhibitors and acute interstitial nephritis. BMJ 341: c4412. DOI 10. 1136/bmj. c4412.
39. Reimer C, Søndergaard B, Hilsted L, Bytzer P (2009) Proton-pump inhibitor therapy induces acid-related symptoms in healthy volunteers after withdrawal of therapy. Gastroenterology 137: 80-87.
40. Robertson DJ, Larsson H, Friis S et al (2007) Proton pump inhibitor use and risk of colorectal cancer: a population-based, case-control study. Gastroenterology 133: 755-760.
41. Sarkar M, Hennessy S, Yang YX (2008) Proton-pump inhibitor use and the risk for community-acquired pneumonia. Ann Intern Med 149: 391-398.
42. Shabajee N, Lamb E, Sturgess I, Sumathipala R (2008) Omeprazole and refractory hypomagnesemia. BMJ 337: 173-175.
43. Sierra F, Suarez M, Rey M, Vela MF (2007) Systematic review: proton pump inhibitor-associated acute interstitial nephritis. Aliment Pharmacol Ther 26: 545-553.
44. Simpson IJ, Marshall MR, Pilmore H et al (2006) Proton pump inhibitors and acute interstitial nephritis: report and analysis of 15 cases. Nephrology 11: 381-385.
45. Smeets HM, Hoes AW, Wit NJ de (2007) Effectiveness and costs of implementation strategies to reduce acid suppressive drug prescriptions: a systematic review. BMC Health Serv Res 7: 177.
46. Southern WN, Rahmani R, Aroniadis O et al (2010) Postoperative Clostridium difficile-associated diarrhea. Surgery 148: 24-30.
47. Targownik LE, Leslie WD (2011) The relationship among proton pump inhibitors, bone disease and fracture. Expert Opin Drug Saf (Epub ahead of print).
48. Teichert M, Noord C van, Uitterlinden AG et al (2011) Proton pump inhibitors and the risk of overanticoagulation during acenocoumarol maintenance treatment. Br J Haematol 153: 379-385.
49. Soest EM van, Rossum LG van, Dieleman JP et al (2008) Proton pump inhibitors and the risk of colorectal cancer. Am J Gastroenterol 103: 966-973.
50. Vestergaard P, Rejnmark L, Mosekilde L (2006) Proton pump inhibitors, histamine H2 receptor antagonists, and other antacid medications and the risk of fracture. Calcif Tissue Int 79: 76-83.
51. Rahden BHA von, Filser J, Germer CT (2011) PPI vs. Fundoplicatio in der Behandlung der gastroösophagealen Refluxkrankheit: Ergebnisse der Cochrane-Metaanalyse und der LOTUS-Studie. Chirurg (im Druck).
52. Wileman SM, McCann S, Grant AM et al (2010) Medical versus surgical management for gastro-oesophageal reflux disease (GORD) in adults. Cochrane Database Syst Rev CD003243.
53. Yang YX, Hennessy S, Propert K et al (2007) Chronic proton pump inhibitor therapy and the risk of colorectal cancer. Gastroenterology 133: 748-754.
54. Yang YX, Lewis JD, Epstein S, Metz DC (2006) Long-term proton pump inhibitor therapy and risk of hip fracture. JAMA 296: 2947-2953.
55. Yang YX, Metz DC (2010) Safety of proton pump inhibitor exposure. Gastroenterology 139: 1115-1127.